Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.

Saved in:
Bibliographic Details
Title: Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial.
Authors: Hoogstad-van Evert JS; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands; Department of Gynecology, Amphia hospital, Breda, the Netherlands., de Jonge PKJD; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Zusterzeel PLM; Department of Gynecology, Radboud university medical center, Nijmegen, the Netherlands., Hobo W; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., van der Waart AB; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Fredrix H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Janssen L; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Wuts M; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Bosmans L; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Spijkers E; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Djojoatmo M; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Rodriguez VC; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., de Goede AL; Department of Pharmacy, Pharmacology and Toxicology, Radboud university medical center, Nijmegen, the Netherlands., van der Reijden B; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., van der Meer A; Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud university medical center, Nijmegen, the Netherlands., Schaap N; Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Bekkers R; Department of Gynecology, Radboud university medical center, Nijmegen, the Netherlands; Department of Obstetrics and Gynecology, Catharina Hospital Eindhoven, the Netherlands; GROW school for oncology and reproduction, Maastricht University, Maastricht, the Netherlands., Jansen JH; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands., Ottevanger N; Department of Medical Oncology, Radboud university medical center, Nijmegen, the Netherlands., Dolstra H; Department of Laboratory Medicine, Laboratory of Hematology, Radboud university medical center, Nijmegen, the Netherlands. Electronic address: harry.dolstra@radboudumc.nl.
Source: Gynecologic oncology [Gynecol Oncol] 2026 Jan; Vol. 204, pp. 91-99. Date of Electronic Publication: 2025 Nov 24.
Publication Type: Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1095-6859
DOI:10.1016/j.ygyno.2025.11.006